304 related articles for article (PubMed ID: 28163793)
1. UroMark-a urinary biomarker assay for the detection of bladder cancer.
Feber A; Dhami P; Dong L; de Winter P; Tan WS; Martínez-Fernández M; Paul DS; Hynes-Allen A; Rezaee S; Gurung P; Rodney S; Mehmood A; Villacampa F; de la Rosa F; Jameson C; Cheng KK; Zeegers MP; Bryan RT; James ND; Paramio JM; Freeman A; Beck S; Kelly JD
Clin Epigenetics; 2017; 9():8. PubMed ID: 28163793
[TBL] [Abstract][Full Text] [Related]
2. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
3. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
4. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.
Piatti P; Chew YC; Suwoto M; Yamada T; Jara B; Jia XY; Guo W; Ghodoussipour S; Daneshmand S; Ahmadi H; Rice J; Bhasin J; Holloway F; Tsai Y; Chihara Y; Liang G
Clin Epigenetics; 2021 Apr; 13(1):84. PubMed ID: 33882992
[TBL] [Abstract][Full Text] [Related]
6. DETECT I & DETECT II: a study protocol for a prospective multicentre observational study to validate the UroMark assay for the detection of bladder cancer from urinary cells.
Tan WS; Feber A; Dong L; Sarpong R; Rezaee S; Rodney S; Khetrapal P; de Winter P; Ocampo F; Jalil R; Williams NR; Brew-Graves C; Kelly JD
BMC Cancer; 2017 Nov; 17(1):767. PubMed ID: 29141603
[TBL] [Abstract][Full Text] [Related]
7. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
8. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
9. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
10. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.
Chen X; Zhang J; Ruan W; Huang M; Wang C; Wang H; Jiang Z; Wang S; Liu Z; Liu C; Tan W; Yang J; Chen J; Chen Z; Li X; Zhang X; Xu P; Chen L; Xie R; Zhou Q; Xu S; Irwin DL; Fan JB; Huang J; Lin T
J Clin Invest; 2020 Dec; 130(12):6278-6289. PubMed ID: 32817589
[TBL] [Abstract][Full Text] [Related]
11. Detection of bladder cancer in urine sediments by a hypermethylation panel of selected tumor suppressor genes.
Pietrusiński M; Kȩpczyński Ƚ; Jȩdrzejczyk A; Borkowska E; Traczyk-Borszyńska M; Constantinou M; Kaƚużewski B; Borowiec M
Cancer Biomark; 2017; 18(1):47-59. PubMed ID: 27814275
[TBL] [Abstract][Full Text] [Related]
12. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic markers of urothelial cancer based on DNA methylation analysis.
Chihara Y; Kanai Y; Fujimoto H; Sugano K; Kawashima K; Liang G; Jones PA; Fujimoto K; Kuniyasu H; Hirao Y
BMC Cancer; 2013 Jun; 13():275. PubMed ID: 23735005
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.
Stasik S; Salomo K; Heberling U; Froehner M; Sommer U; Baretton GB; Ehninger G; Wirth MP; Thiede C; Fuessel S
Clin Biochem; 2019 Feb; 64():60-63. PubMed ID: 30528938
[TBL] [Abstract][Full Text] [Related]
15. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
[TBL] [Abstract][Full Text] [Related]
16. Integrative functional genetic-epigenetic approach for selecting genes as urine biomarkers for bladder cancer diagnosis.
Eissa S; Matboli M; Essawy NO; Kotb YM
Tumour Biol; 2015 Dec; 36(12):9545-52. PubMed ID: 26138586
[TBL] [Abstract][Full Text] [Related]
17. Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study.
Hosen MI; Sheikh M; Zvereva M; Scelo G; Forey N; Durand G; Voegele C; Poustchi H; Khoshnia M; Roshandel G; Sotoudeh M; Nikmanesh A; Etemadi A; Avogbe PH; Chopard P; Delhomme TM; Foll M; Manel A; Vian E; Weiderpass E; Kamangar F; Boffetta P; Pharaoh PD; Dawsey SM; Abnet CC; Brennan P; McKay J; Malekzadeh R; Calvez-Kelm FL
EBioMedicine; 2020 Mar; 53():102643. PubMed ID: 32081602
[TBL] [Abstract][Full Text] [Related]
18. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments.
Chung W; Bondaruk J; Jelinek J; Lotan Y; Liang S; Czerniak B; Issa JP
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1483-91. PubMed ID: 21586619
[TBL] [Abstract][Full Text] [Related]
19. Highly Sensitive and Specific Detection of Bladder Cancer via Targeted Ultra-deep Sequencing of Urinary DNA.
Ward DG; Baxter L; Ott S; Gordon NS; Wang J; Patel P; Piechocki K; Silcock L; Sale C; Zeegers MP; Cheng KK; James ND; Bryan RT;
Eur Urol Oncol; 2023 Feb; 6(1):67-75. PubMed ID: 35410825
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]